MC2 Therapeutics’ Wynzora Cream Approved for Plaque Psoriasis

The FDA has approved MC2 Therapeutics’ Wynzora cream (calcipotriene and betamethasone dipropionate) for treatment for adults with plaque psoriasis.

The approval was based on the results of a phase 3 study in which the skin of patients given the once-daily topical treatment improved to “clear” or “almost clear” by eight weeks.

The product is currently being reviewed in the EU for treatment of plaque psoriasis.